Please ensure Javascript is enabled for purposes of website accessibility

Cronos Group and MediPharm Labs Sign Vaporizer Deal

By Eric Volkman - Sep 20, 2019 at 6:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This is not the first time the two companies have worked together.

Marijuana stocks Cronos Group (CRON 7.26%) and MediPharm Labs (MEDIF -13.30%) are extending their cooperation with a new supply deal, according to a press release published Thursday. Under the terms of the multiyear contract manufacturing agreement, MediPharm -- a specialist in cannabis extraction -- will fill and package vaporizers for Cronos' COVE line of cannabis products.

Neither the terms nor the financial details of the arrangement were provided.

This is not the first time the two companies have cooperated. In May, they signed contracts in which MediPharm agreed to supply bulk resin and cannabis concentrate to Cronos.

A vape pen and marijuana leaves on a white surface.

Image source: Getty Images.

Cronos has gone the partnership route in various ways with several companies. Perhaps its most notable tie-up is with Altria Group, in which Altria invested $1.8 billion for a 45% holding in the company. It's very possible that at some point these two makers of complementary goods will find a way to cooperate in the development of new products for the cannabis market.

Cronos considers the latest cooperation with MediPharm to be a foundation for a new line of products. In MediPharm's press release, Cronos CEO Mike Gorenstein was quoted as saying that "[w]orking with MediPharm Labs gives us the quality and optionality that we are looking for as we introduce our proprietary vape pen formulations."

"We are committed to continuing to the lead the industry responsibly as derivative products are introduced to the expanding Canadian marketplace," Gorenstein continued. Next month, Canada's "next wave" of cannabis legislation will see the market opened for derivative products such as edibles, extracts, and infused beverages. 

COVE is a higher-end line of cannabis flowers and oils. It is one of Cronos' three retail brands, the others being Spinach (focused on more youthful consumers) and Peace Naturals, a line that emphasizes health and wellness.

Neither stock did particularly well following the announcement. Cronos closed down 6.7% on the day, while MediPharm was off by 3.5%. Investors might be a bit skittish about the connection to vaping, an activity that has become more controversial lately due to fatalities allegedly resulting from it. 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Stock Quote
Cronos Group
CRON
$3.40 (7.26%) $0.23
MediPharm Labs Corp. Stock Quote
MediPharm Labs Corp.
MEDIF
$0.07 (-13.30%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.